by Barry101 | Nov 28, 2023 | Press Release
AIM Will Convene Annual Meeting on December 1st and then Adjourn Until December 29th to Give Delaware Court Additional Time to Deliver Ruling in Activist Group Litigation OCALA, Fla. – AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the...
by Barry101 | Nov 27, 2023 | Press Release
Extends certain exclusive U.S. rights to Ampligen for cancer and ME/CFS through 2039 Management discusses patent issuance and what this means in a brief video: here OCALA, Fla., Nov. 27, 2023 — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the...
by Barry101 | Nov 21, 2023 | Press Release
No severe adverse events reported to date Topline data expected as early as Q1 2024 OCALA, Fla., Nov. 21, 2023 — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced the last subject has completed treatment in...
by Barry101 | Nov 15, 2023 | Press Release
– Highlights continued execution across Ampligen® clinical development programs – Company is well positioned to achieve multiple value-driving milestones during remainder of 2023 and 2024 – Will host conference call and webcast today, November...
by Barry101 | Nov 14, 2023 | Press Release
Data published in The Journal for ImmunoTherapy of CancerOCALA, Fla., Nov. 14, 2023 — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced the publication of results from the Phase 1 study at Roswell Park...
by Barry101 | Nov 9, 2023 | Press Release
OCALA, Fla., Nov. 09, 2023 — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), announced today that management will host a conference call and webcast to discuss the Company’s Q3 2023 operational and financial...
